X-linked myopathy with excessive autophagy, known as XMEA, is an extraordinarily rare neuromuscular disorder that affects almost exclusively males, with no affected females reported to date. Symptoms most often begin in childhood, though congenital and late-onset cases have been described. Patients experience slowly progressive weakness of the proximal muscles, typically starting in the lower limbs and gradually spreading, frequently leading to loss of the ability to walk by mid-adulthood. Although the condition has traditionally been viewed as confined to skeletal muscle, growing clinical evidence points to respiratory involvement as relatively common, and cardiac abnormalities have been documented in a subset of patients.

The root cause of XMEA lies in mutations in a gene called Vma21, which encodes an essential assembly chaperone for the vacuolar H⁺-ATPase, or V-ATPase, the principal proton pump responsible for acidifying lysosomes, the membrane-bound compartments that serve as the cell’s digestive and recycling machinery. Lysosomes require a highly acidic interior to activate the hydrolytic enzymes that break down cellular cargo. When Vma21 is deficient, V-ATPase complexes fail to assemble properly, lysosomal acidification falters, and undegraded autophagic material accumulates in muscle fibers as characteristic vacuoles. Under the microscope, muscle biopsies from patients display cytoplasmic vacuoles studded with sarcolemmal and basal lamina proteins, complex fiber splitting, deposition of the complement membrane attack complex C5b-9, and, in some cases, aggregates of autophagy receptors such as SQSTM1/p62. Two features in particular, reduplication of the basal lamina and so-called autophagic vacuoles with sarcolemmal features, structures bounded by membranes normally found at the muscle cell surface, define the disease and distinguish it from the related Danon disorder, which arises from loss of the lysosomal membrane protein LAMP2.

Despite the identification of Vma21 as the culprit gene, researchers have struggled to explain precisely how its deficiency drives progressive muscle degeneration, largely because no mammalian model reliably reproduced the disease’s hallmark structural features. A recently described zebrafish model, for instance, showed autophagic impairment but failed to develop the signature vacuoles and basal lamina abnormalities. The new study closes that gap with two complementary mouse models generated using the CRISPR-Cas9 system to insert loxP sites flanking the X-linked Vma21 gene, enabling conditional deletion with Cre recombinase.

The first model employed the muscle creatine kinase promoter to delete Vma21 in both skeletal and cardiac muscle from early development. Because Vma21 resides on the X chromosome, male mice were used to guarantee complete gene inactivation. The result was dramatic: mice lacking Vma21 in both striated muscles were born at expected frequencies but grew poorly and died uniformly between postnatal days 22 and 23. Histological examination revealed that the lethality stemmed not from skeletal muscle but from the heart. While the skeletal muscles of these animals showed no evident myopathy at the time of death, their hearts displayed severe cardiomyopathy, with inflammatory infiltration and extensive cytoplasmic vacuolization. Echocardiography at postnatal day 18 confirmed markedly impaired contractile function, with reduced fractional shortening and elevated filling pressures, identifying heart failure as the cause of death. Biochemical analysis of cardiac tissue revealed the accumulation of LAMP2, poly-ubiquitinated proteins, LC3B-II, and SQSTM1, the molecular fingerprint of stalled autophagy, while skeletal muscle at the same age showed no significant changes in bulk autophagy markers.

The researchers interpret this striking cardiac vulnerability in light of the genetics of human XMEA. In patients, pathogenic variants reduce but do not abolish Vma21 transcript production, leaving residual protein function in what is termed a hypomorphic mechanism. The knockout mice, by contrast, suffer near-complete loss of the protein, and the findings suggest that cardiac muscle tolerates profound autophagic impairment far less well than skeletal muscle. A parallel can be drawn with Danon disease, in which LAMP2 deficiency produces severe cardiomyopathy alongside skeletal muscle pathology. The authors note that emerging clinical reports of cardiac abnormalities in some XMEA patients suggest cardiac involvement may be underrecognized, and they underscore the importance of systematic cardiac evaluation in affected individuals, even though cardiac disease is relatively uncommon in the human condition.

To capture the skeletal muscle disease without the confounding early lethality, the team engineered a second model in which Vma21 deletion is restricted to skeletal muscle and can be triggered at will in adult animals using a tamoxifen-inducible Cre recombinase under the control of the human skeletal actin promoter. After two months of tamoxifen treatment, Vma21 protein was robustly depleted from the tibialis anterior, gastrocnemius, and quadriceps muscles, while expression in heart, liver, and kidney remained untouched. The mice began losing weight relative to controls, and by four months they showed significantly reduced grip endurance, a functional echo of the progressive weakness seen in patients.

The histological story unfolded gradually. At two months, despite efficient Vma21 loss, the muscle looked essentially normal. At three months, fibers of increasingly variable size appeared, along with early fiber splitting and nuclei migrating to the center of fibers, a classic sign of muscle pathology. By four months the changes were unmistakable, and at six months they had intensified, with quantification confirming significant increases in the percentage of fibers with internalized nuclei, the percentage of fibers exhibiting splitting, and the coefficient of variation of fiber cross-sectional area. The delayed onset carries its own biological message. Mature muscle fibers possess unusually long-lived lysosomes, the authors suggest, and those assembled before Vma21 deletion may continue functioning for weeks, masking the defect until newly formed, improperly acidified lysosomes gradually accumulate and overwhelm the fiber’s degradative capacity.

Molecular analyses of the myopathic muscle confirmed autophagic dysregulation. Levels of LAMP2, poly-ubiquitinated proteins, and LC3B-II rose substantially by four months, yet messenger RNA levels for LC3B and SQSTM1 were unchanged, demonstrating that the protein buildup reflects failed degradation rather than increased production. Immunofluorescence revealed LAMP2, LC3B, SQSTM1, and poly-ubiquitin-positive puncta clustered conspicuously at the periphery of muscle fibers. Crucially, co-staining for laminin and dystrophin exposed both basal lamina reduplication and authentic autophagic vacuoles with sarcolemmal features, vacuoles that carried lysosomal and autophagy markers within their lumens. Transmission electron microscopy then revealed the fine structure: membrane-bound vacuoles containing partially undegraded electron-dense material, frequently piled up in the subsarcolemmal region, alongside irregular membrane regions studded with clusters of small vesicles, some of which had apparently escaped into the extracellular space.

It was this last observation that led the team to an entirely new discovery. Reasoning that peripheral vacuole accumulation might reflect increased exocytosis of undegraded material, they examined CD63, a marker of late endosomes and exosomes. Control muscle showed minimal CD63 staining, but Vma21-deficient fibers were studded with CD63-positive structures enriched at their periphery. Remarkably, these structures colocalized strongly with the complement membrane attack complex C5b-9 at the sarcolemma. When the researchers turned to stored muscle biopsies from genetically confirmed XMEA patients, they found the same pattern: increased CD63 staining colocalizing with C5b-9, indicating that this feature is conserved between mouse and human disease. Complement deposition has been recognized in XMEA muscle for years, but its origin has remained mysterious. The new findings raise the possibility that altered vesicle trafficking or the exposure of vesicle-associated components at the fiber surface recruits the complement cascade, forging a mechanistic link between failed autophagy, disturbed membrane traffic, and inflammatory attack on muscle fibers.

The sarcolemmal C5b-9 deposition also suggests an immediate therapeutic avenue. Complement inhibition with the C5 blocker eculizumab has recently been reported to improve clinical measures in a patient with dysferlinopathy, another muscle disease marked by complement deposition at the muscle membrane. Although the triggers of complement activation may differ between the two disorders, the authors propose that complement-directed therapies could now be tested directly in their Vma21-deficient mice to determine whether the complement system actively drives disease progression in XMEA.

The study is not without limitations. The knockout models achieve near-complete loss of Vma21, whereas most patients retain partial function; only male mice were analyzed, leaving open questions about X-chromosome inactivation and sex-specific severity in females; and the precise temporal relationship among autophagic failure, vesicle trafficking changes, membrane remodeling, and weakness remains to be fully mapped, as does the question of whether altered vesicle traffic drives disease or represents a compensatory response. Even so, the models constitute a robust mammalian platform that reproduces the progressive myopathy, autophagic dysregulation, sarcolemmal vacuoles, and basal lamina reduplication that define XMEA. For a disease that has lacked both animal models and treatment options, the work offers researchers, for the first time, a physiologically relevant system in which to dissect mechanisms and screen disease-modifying therapies, along with a fresh biological target, the CD63-positive vesicle pathway and its uneasy partnership with complement, that may prove central to how this rare muscle disease takes its toll.

Dynamin 2 (DNM2) plays a pivotal role in skeletal muscle and peripheral nerve physiology, orchestrating key processes such as endocytosis, vesicle scission, and actin cytoskeleton remodeling. Pathogenic variants of DNM2 have been linked to centronuclear myopathy (CNM), characterized by muscle weakness and structural abnormalities in muscle fibers, as well as to hereditary neuropathies that affect the peripheral nervous system, leading to sensory and motor deficits. Until now, these mutations were studied in isolation, with each mutation causing distinct and non-overlapping clinical features. The revelation that combining two detrimental mutations can paradoxically rescue both conditions challenges the classical view of genetic pathogenesis and opens new therapeutic avenues.

The investigators employed an integrative suite of techniques, including molecular genetics, cell biology, and advanced imaging, to unravel the interplay between these mutations. They engineered cellular and animal models harboring individual or combined dynamin 2 mutations associated with myopathy and neuropathy. Intriguingly, cells expressing both mutations showed a restoration of key cellular functions that are severely compromised when either mutation is present alone. This functional rescue phenomenon was evidenced by normalized endocytic activity, corrected actin organization, and improved mitochondrial dynamics, all of which are essential for muscle and nerve cell health.

Mechanistically, the study suggests that the two mutations exert compensatory effects on the dynamin 2 protein’s conformation and oligomerization state. Dynamin 2 assembles into helices around membrane necks to catalyze membrane fission; perturbations in this assembly often underlie disease processes. The team’s biochemical assays revealed that myopathy-linked mutations tend to stabilize a hyperactive conformation, while neuropathy-associated mutations promote a hypoactive form. When combined, these opposing conformational biases appear to counterbalance each other, realigning dynamin 2 function closer to the wild type state. This insight sheds light on the allosteric regulation of dynamin 2 and highlights the structural plasticity that underpins its functional versatility.

From a cellular perspective, the rescue effect manifested in several critical pathways. For example, in muscle cells, mitochondrial morphology and distribution, often fragmented or aggregated in myopathic conditions, were normalized. Given that mitochondria provide the energetic foundation necessary for muscle contraction and nerve transmission, this normalization is likely a key contributor to the phenotypic improvement. Similarly, peripheral neurons exhibited restored axonal transport and synaptic vesicle recycling, processes heavily reliant on proper dynamin 2 activity. These findings underscore the interconnectedness of intracellular trafficking, energy metabolism, and cytoskeletal architecture in neuromuscular health.

The implications for clinical genetic counseling are profound. Traditionally, the presence of multiple pathogenic mutations in a single gene is thought to worsen clinical outcomes through additive or synergistic effects. However, this study suggests a more nuanced paradigm where certain deleterious mutations may interact in an antagonistic manner, potentially alleviating disease severity. This concept demands a reexamination of genotype-phenotype correlations in dynamin 2-related disorders and possibly other genetic diseases characterized by allelic heterogeneity.

In addition to its clinical ramifications, the study recalibrates our understanding of protein dynamics in health and disease. Dynamin 2’s ability to toggle between conformational states facilitates its engagement in multiple cellular events. The identification of mutation combinations that restore this dynamic balance provides a template for rational drug design. Small molecules or genetic therapies aimed at modulating dynamin 2 conformation could mimic the beneficial interaction observed between these mutations, offering hope for patients afflicted by CNM or hereditary neuropathies.

Furthermore, the research underscores the value of combinatorial genetic models in revealing unexpected biological insights. Such models help decipher complex molecular networks governing cell physiology, which are often overlooked in single-mutation analyses. The study’s success also exemplifies the power of cross-disciplinary approaches, merging genetics, structural biology, and neuroscience to tackle the multifaceted nature of neuromuscular diseases.

The therapeutic potential of this discovery extends beyond dynamin 2 mutations alone. Many diseases arise from perturbations in protein conformation and function; thus, identifying compensatory mutation pairs or pharmacological agents that stabilize beneficial conformations could revolutionize treatment strategies. The concept of “genetic compensation” or “intragenic suppression” may emerge as a cornerstone in personalized medicine, offering novel strategies to harness natural or engineered interactions within proteins to correct dysfunction.

While the in vivo models exhibited significant phenotypic rescue, the study acknowledges remaining challenges before clinical translation. The complexity of human physiology and genetic background variability means that the beneficial effects observed in controlled experimental settings must be cautiously extrapolated. Future work will need to explore the extent to which such mutation combinations can be safely mimicked or induced in patients, as well as whether similar compensatory phenomena exist in other genes implicated in neuromuscular diseases.

The findings also provoke intriguing evolutionary questions. The balanced opposing conformations induced by distinct mutations raise the possibility that certain genetic variants may persist in populations due to hidden compensatory effects. This insight could reshape our understanding of mutation selection pressures and epistatic interactions in human genetics, highlighting the delicate equilibrium between protein structure, function, and disease.

In conclusion, the work of Goret, Edelweiss, Jehl, and colleagues represents a paradigm shift in the genetics of neuromuscular disorders, showcasing how combining two detrimental mutations in dynamin 2 paradoxically rescues both myopathy and neuropathy phenotypes. By revealing the molecular and cellular mechanisms underlying this unexpected phenomenon, the study opens innovative pathways toward targeted therapies that restore protein function through modulation of conformational equilibria. This unexpected synergy between mutations stimulates a broader reevaluation of genetic pathogenesis and therapeutic design in neuromuscular medicine and beyond.

The full study offers a detailed roadmap for researchers, clinicians, and pharmaceutical developers aiming to harness the intricacies of intra-protein mutation interactions to ameliorate or cure diseases currently deemed intractable. As the boundaries between genetics, cell biology, and therapeutic science continue to blur, discoveries like this illuminate a future where precision medicine is grounded not only in identifying mutations but also in understanding and manipulating their complex interrelations.

Subject of Research: The interaction between dynamin 2 mutations that cause myopathy and neuropathy, and how combining these mutations rescues both disease phenotypes.

Article Title: Combining dynamin 2 myopathy and neuropathy mutations rescues both phenotypes.

Article References:
Goret, M., Edelweiss, E., Jehl, J. et al. Combining dynamin 2 myopathy and neuropathy mutations rescues both phenotypes. Nat Commun 16, 4667 (2025). https://doi.org/10.1038/s41467-025-59925-6

Image Credits: AI Generated